# A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies

> **NCT07220616** · PHASE1,PHASE2 · RECRUITING · sponsor: **Daiichi Sankyo** · enrollment: 420 (estimated)

## Conditions studied

- Hematological Malignancies

## Interventions

- **DRUG:** DS3790a
- **DRUG:** Combination drug
- **DRUG:** Combination drug

## Key facts

- **NCT ID:** NCT07220616
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-16
- **Primary completion:** 2030-11-30
- **Final completion:** 2030-11-30
- **Target enrollment:** 420 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07220616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07220616, "A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07220616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*